Komori
Other Disclosures4461DKS Co.Ltd.Materials and Chemicals

New technology confirmed to expand design flexibility for solid dispersions; poster presentation at the 41st Annual Meeting of the Japanese Society of Pharmaceutical Technology

第一工業製薬 confirmed through joint research with the University of Shizuoka that adding sucrose fatty acid esters after preparing a solid dispersion can improve the dissolution of poorly soluble substances. The research findings are scheduled to be presented in a poster at the 41st Annual Meeting of the Japanese Society of Pharmaceutical Technology on 4 June 2026.

Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

DK EsterSucrose fatty acid esters
Applicable field (uses covered by this announcement)

Pharmaceutical development, formulation design, and improving the dissolution and absorption of poorly soluble substances

Relationship between the counterparty and the company
DKS Co.Ltd.4461
Relationship with the Company

Joint research conducted.

CounterpartyUniversity of Shizuoka, a public university corporation

Location: Shizuoka City; President: Imai Yasuyuki (今井康之). Public university corporation.

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Public Interest Incorporated Association, Japanese Society of Pharmaceutical Technology, 41st Annual Meeting

Announced details
ItemDetails
Names of Products / Services CoveredDK Ester, Sucrose fatty acid esters
CounterpartyUniversity of Shizuoka, a public university corporation
Counterparty overviewLocation: Shizuoka City; President: Imai Yasuyuki (今井康之). Public university corporation.
Relationship with the CompanyJoint research conducted.
Applicable areaPharmaceutical development, formulation design, and improving the dissolution and absorption of poorly soluble substances
SourcePublic Interest Incorporated Association, Japanese Society of Pharmaceutical Technology, 41st Annual Meeting
Items this document does not state (12)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The importance of technologies that improve dissolution and absorption in pharmaceutical development is increasing against the backdrop of a rise in poorly soluble substances.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
New technology confirmed to expand design flexibility for solid dispersions; poster presentation at the 41st Annual Meeting of the Japanese Society of Pharmaceutical Technology | DKS Co.Ltd. (4461) timely disclosure | Komori